Taysha Gene Therapies (TSHA) Accumulated Expenses (2019 - 2026)
Taysha Gene Therapies (TSHA) posted Accumulated Expenses of $4.9 million for Q1 2026, up 35.09% sequentially from $3.6 million in Q4 2025, and up 93.27% YoY from $2.5 million in Q1 2025.
Taysha Gene Therapies (TSHA) Accumulated Expenses (2019 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Accumulated Expenses for 8 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 93.27% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 93.27% YoY) and the FY2025 annual result came in at $3.6 million, up 109.51% from the prior year.
- Accumulated Expenses climbed to $4.9 million in Q1 2026 per TSHA's latest filing, from $3.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $19.0 million in Q2 2022 and troughed at $1.6 million in Q1 2024.
- A 5-year average of $8.8 million and a median of $5.7 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 90.51% in 2024, then surged 365.02% in 2025.
- Over 5 years, Accumulated Expenses stood at $18.3 million in 2022, then sank by 81.04% to $3.5 million in 2023, then sank by 50.56% to $1.7 million in 2024, then soared by 109.51% to $3.6 million in 2025, then jumped by 35.09% to $4.9 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $4.9 million, $3.6 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.81 Mn |
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 5.35 Mn |
| Jun 30, 2025 | 12.15 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 12.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 5.70 Mn |
| Jun 30, 2023 | 7.02 Mn |
| Mar 31, 2023 | 16.60 Mn |
| Dec 31, 2022 | 18.29 Mn |
| Sep 30, 2022 | 17.89 Mn |
| Jun 30, 2022 | 18.99 Mn |
| Mar 31, 2022 | 15.08 Mn |
| Dec 31, 2021 | 7.70 Mn |
| Sep 30, 2021 | 21.16 Mn |